ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Microscopic Polyangiitis"

  • Abstract Number: 0686 • ACR Convergence 2023

    Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

    David Jayne1, Duvuru Geetha2, Christian Pagnoux3, Sebastian Sattui4 and Peter Merkel5, 1University of Cambridge, Cambridge, United Kingdom, 2Johns Hopkins University, Baltimore, MD, 3Mount Sinai Hospital, Toronto, ON, Canada, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Older adults are at increased risk of glucocorticoid (GC)-related toxicity; minimization of GCs is a major focus for treatment of patients with ANCA-associated vasculitis…
  • Abstract Number: 0689 • ACR Convergence 2023

    Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2

    Bryce Barr, Kim Cheema, Aurore Fifi-Mah, Stephanie Garner, Louis Girard and Jeffrey Ma, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Glomerulonephritis represents a severe manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and is associated with substantial morbidity and mortality. Therefore, maximal recovery…
  • Abstract Number: 0725 • ACR Convergence 2023

    Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Sophie Nagle1, Yann Nguyen2, Xavier Puéchal3, Dimitri Titeca-Beauport4, Thomas Crépin5, Rafik Mesbah6, Idris Boudhabhay7, Gregory Pugnet8, Juliette Woessner9, Roderau Outh10, Céline Lebas11, Antoine Néel12, alexandre Karras13, Eric Hachulla11, Benjamin Subran14, Philippe Kerschen15, Mathieu Gerfaud-Valentin16, Stéphane Vinzio17, Tiphaine Goulenok18, Raphael Borie19, Sébastien Humbert20, Yurdagul Uzunhan21, Sarah Melboucy-Belkhir22, Jean-Baptiste Gouin23, Mary-Jane Guerry24 and Benjamin Terrier25, 1AP-HP Cochin Hospital, Paris, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 4CHU Amiens, Amiens, France, 5Amiens University Hospital, Amiens, France, 6Boulogne Hospital (CH), Boulogne, France, 7Necker University Hospital, Paris, France, 8CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 9Avignon Hospital (CH), Avignon, France, 10Perpignan Hospital (CH), Perpignan, France, 11Lille University Hospital, Lille, France, 12CHU Nantes, Nantes, France, 13HEGP - APHP, Paris, France, 14Croix Saint Simon Hospital, Paris, France, 15Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, 16Lyon University Hospital, Lyon, France, 17Grenoble Hospital (CH), Grenoble, France, 18Assistance Publique Hopitaux de Paris, Paris, France, 19Bichat-Claude Bernard, Universite de Paris, Paris, France, 20Besançon University Hospital, Besançon, France, 21AP-HP, Bobigny, France, 22Saint Quentin Hospital, Saint-Quentin, France, 23Vannes Hospital (CH Bretagne Atlantique), Vannes, France, 24Valenciennes Hospital (CH), Valenciennes, France, 25Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
  • Abstract Number: 0857 • ACR Convergence 2023

    Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan

    Duvuru Geetha1, Frank Cortazar2, alexandre Karras3, Annette Bruchfeld4, Huibin Yue5, Peter Merkel6 and David Jayne7, 1Johns Hopkins University, Baltimore, MD, 2New York Nephrology, Watervliet, NY, 3HEGP - APHP, Paris, France, 4Karolinska Institutet, Stockholm, Sweden, 5Amgen, Inc., Thousand Oaks, CA, 6University of Pennsylvania, Philadelphia, PA, 7University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
  • Abstract Number: 1535 • ACR Convergence 2023

    Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study

    Ji In Jung1, Jun Won Park2, Song Jihun3, Seulggie Choi2, Sun Jae Park3, Sang Min Park2 and Eun Young Lee4, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea, 3Seoul National University Graduate School, Seoul, South Korea, 4Seoul National University College of Medicine, Seoul, South Korea

    Background/Purpose: Previous studies on AAV have shown that the epidemiology and clinical features of GPA and MPA differ among countries. Considering their high mortality and…
  • Abstract Number: 1538 • ACR Convergence 2023

    Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades

    Mahmut Kaymakci1, Mohanad Elfishawi1, Hannah Langenfeld2, Andrew Hanson2, Cynthia Crowson1, Melanie Bois1, Umar Ghaffar1, Ulrich Specks1, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
  • Abstract Number: 1553 • ACR Convergence 2023

    Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

    Yeliz Yagiz Ozogul1, Sinem Nihal Esatoglu2, Murat Ozogul3, Osman Kizilkilic4, Yesim Ozguler5, Ugur Uygunoglu6, Vedat Hamuryudan2 and Gulen Hatemi2, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey

    Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
  • Abstract Number: 2375 • ACR Convergence 2023

    Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7

    Shoichi Fukui1, Haruna Matsuo2, Kanako Kojima3, Shota Kurushima1, Tohru Michitsuji4, Yoshika Tsuji5, Toshimasa Shimizu3, Masataka Umeda3, Remi Sumiyoshi5, Takashi Igawa1, Tomohiro Koga5, Shin-ya Kawashiri1, Naoki Iwamoto1, Tomoki Origuchi1 and Atsushi Kawakami1, 1Nagasaki University, Nagasaki, Japan, 2Nagasaki University, Nagasaki City, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, 5Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan

    Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
  • Abstract Number: 2376 • ACR Convergence 2023

    Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis

    Teppei Hashimoto1, Kazuteru Noguchi2, Yuko Minagawa2, Takeo Abe2, Masao Tamura2, Tetsuya Furukawa1, Naoto Azuma2 and Kiyoshi Matsui1, 1Hyogo Medical University, Nishinomiya, Japan, 2Hyogo Medical University, School of Medicine, Nishinomiya, Japan

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease requiring complex management due to a lack of suitable biomarkers. Elevated or persistently positive…
  • Abstract Number: 0526 • ACR Convergence 2022

    Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

    Lynn Fussner1, Luis Felipe Flores-Suarez2, Rodrigo Cartin-Ceba3, Ulrich Specks3, P. Gerard Cox4, David Jayne5, Peter Merkel6 and Michael Walsh4, 1The Ohio State University, Columbus, OH, 2Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, 3Mayo Clinic, Rochester, MN, 4McMaster University, Hamilton, ON, Canada, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
  • Abstract Number: 0527 • ACR Convergence 2022

    Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
  • Abstract Number: 1080 • ACR Convergence 2022

    Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
  • Abstract Number: 1948 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort

    Hyun Ho Lee1, Lauren Blazek2 and Eveline Wu3, 1The University of North Carolina Chapel Hill, Chapel Hill, NC, 2UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, NC

    Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
  • Abstract Number: 0436 • ACR Convergence 2022

    Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study

    Julien Culerrier1, Yann Nguyen2, Omer Karadag3, Sule Yasar Bilge4, Tuba DEMIRCI YILDIRIM5, Tahir Saygin Öğüt6, Veli Yazisiz6, Cemal Bes7, Ayse Cefle8, Oznur Sadioglu Cagdas9, Ayten Yazici8, Andreas Kronbichler10, David Jayne10, Alexis Regent11, Vitor Teixeira12, Sylvain Marchand-Adam13, PIerre Duffau14, Saskia Oro15, Baptiste Andre16, Luminita Luca17, Sarah Lechtman18, Achille Aouba19, Celine Lebas20, Amélie Servettaz21, Amandine Dernoncourt22, Marc Ruivard23, Anne-Marie Milesi24, Vincent Poindron25, Patrick Jego26, Roberto Padoan27, Paolo Delvino28, Frédéric Vandergheynst29, Christian Pagnoux30, Elaine Yacyshyn31, Peter Lamprecht32, Oliver Flossmann33, Xavier Puéchal11 and Benjamin Terrier11, 1Université Paris Cité, Paris, France, Paris, France, 2AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 3Hacettepe University, Ankara, Turkey, 4Eskişehir Osmangazi Üniversity, Eskisehir, Turkey, 5Dokuz Eylul University, İzmir, Turkey, 6Akdeniz University, Antalya, Turkey, 7Bahçeşehi University, Istanbul, Turkey, 8Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 9Kocaeli University, Kocaeli, Turkey, 10University of Cambridge, Cambridge, United Kingdom, 11National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 12Hospital de Faro, CHUA, Lisbon, Portugal, 13Tours University Hospital, Tours, France, 14CHU Bordeaux, Bordeaux, France, 15Assistance Publique - Hôpitaux de Paris., Paris, France, 16Hôpital de la Timone, Marseille, Marseille, France, 17CHU de Poitiers, Poitiers, France, 18CHU Nice, Nice, France, 19Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 20CHRU Lille, Lille, France, 21CHU Reims, Reims, France, 22CHU Amiens - Picardie, Amiens, France, 23Clermont Ferrand University Hospital, Clermont-Ferrand, France, 24Centre hospitalier de Vichy, Vichy, France, 25Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 26CHU Rennes, Paris, France, 27University of Padova, Padova, Italy, 28Università di Pavia, Vercelli, Italy, 29Professeur de Médecine Interne et Sémiologie médicale, Directeur de la Clinique de Médecine Interne Générale, Université Libre de Bruxelles, Bruxelles, France, 30Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 31University of Alberta, Edmonton, AB, Canada, 32Department of Rheumatology University of Lübeck Ratzeburger Allee, Lübeck, Germany, 33Royal Berkshire Hospital, Reading, United Kingdom

    Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…
  • Abstract Number: 0439 • ACR Convergence 2022

    Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles

    Lynn Fussner1, David Cuthbertson2, Peter Grayson3, David Jayne4, Carol McAlear5, Michael Walsh6, Katherine Siminovitch7, Ulrich Specks8 and Peter Merkel9, 1The Ohio State University, Columbus, OH, 2University of South Florida, Tampa, FL, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4University of Cambridge, Cambridge, United Kingdom, 5Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 6McMaster University, Hamilton, ON, Canada, 7University of Toronto, Toronto, ON, Canada, 8Mayo Clinic, Rochester, MN, 9University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology